EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies

Tae Min Kim iD, Stephen K Williamson, Kyriakos P Papadopoulos, Omid Hamid, Grace K Dy, Ray McDermott, Ariel Birnbaum, John M Kaczmar, Nehal Lakhani, Danny Rischin, Debashis Sarker, Afshin Dowlati und 14 weitere

Cancer · 01.05.2026 · 132 (9)

DOI: 10.1002/cncr.70396 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, online erschienen am 24.04.2026. Verfasst von Tae Min Kim und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Antigens, CD, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The dose escalation phase of a first‐in‐human (FIH) study demonstrated acceptable safety and preliminary antitumor activity of fianlimab (anti‐lymphocyte activation gene‐3 [LAG‐3]) as monotherapy and in combination with cemiplimab (anti‐programmed cell death‐1 [PD‐1]). Here, the authors present safety and clinical activity data from the dose‐expansion portion of the FIH study in patients with advanced non–small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), head and neck squamous cell carcinoma (HNSCC), and cutaneous squamous cell carcinoma (CSCC).

Methods

Anti–PD‐1/PD‐L1 naive (N) or experienced (E) patients with advanced NSCLC, ccRCC, HNSCC, and CSCC were enrolled in this phase 1 study (NCT03005782). Patients received fianlimab 1600 mg plus cemiplimab 350 mg intravenously every 3 weeks for up to 24 months. The primary end point was the objective response rate (ORR) per RECIST 1.1.

Results

Investigator‐assessed ORR was 27% in NSCLC‐N (four partial responses [PRs]), 7% in NSCLC‐E (one PR), 20% in ccRCC‐N (three PRs), 7% in ccRCC‐E (one PR), 33% in HNSCC‐N (five PRs), 7% in HNSCC‐E (one PR), and 20% CSCC‐E (two complete responses; one PR). The most common treatment‐related treatment‐emergent adverse events among patients across all cohorts were fatigue (15%), rash (12%), pruritus (10%), infusion‐related reaction (10%), and adrenal insufficiency (10%).

Conclusions

Fianlimab plus cemiplimab demonstrated modest clinical efficacy with an acceptable safety profile in patients with advanced malignancies across several tumor types mostly in treatment‐naive patients. Further investigation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAntigens, CDAntibodies, MonoclonalHumansMaleFemaleMiddle AgedAgedCarcinoma, Non-Small-Cell LungCutaneous Squamous Cell CarcinomaLymphocyte Activation Gene 3 ProteinCarcinoma, Renal CellLung NeoplasmsAdultCombined Antibody TherapeuticsKidney NeoplasmsAged, 80 and overSquamous Cell Carcinoma of Head and Neck

Stichwörter der Autor:innen

LAG‐3PD‐1advanced malignanciescemiplimabfianlimab

Substanzen

Antibodies, Monoclonal, HumanizedcemiplimabLymphocyte Activation Gene 3 ProteinAntigens, CDCombined Antibody TherapeuticsLag3 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, The University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Clinical Research, START San Antonio, The START Center for Cancer Research, San Antonio, Texas, USA.
  • Melanoma Center, The Angeles Clinic and Research Institute, Los Angeles, California, USA.
  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
  • Tallaght University Hospital, Dublin, Ireland.

ORCID-Profile: Tae Min Kim, Byoung Chul Cho

Förderung

  • Regeneron Pharmaceuticals Inc

Zitieren

APA

Kim, T. M., Williamson, S. K., Papadopoulos, K. P., Hamid, O., Dy, G. K., McDermott, R., Birnbaum, A., Kaczmar, J. M., Lakhani, N., Rischin, D., Sarker, D., Dowlati, A., Zhu, X. H., Malhotra, J., Pouliot, J. F., Mani, J., Brennan, L., Fang, F., Chen, S., …, & Cho, B. C. (2026). Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies. Cancer, 132(9). https://doi.org/10.1002/cncr.70396

Vancouver

Kim TM, Williamson SK, Papadopoulos KP, Hamid O, Dy GK, McDermott R, et al. Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies. Cancer. 2026;132(9). doi:10.1002/cncr.70396

BibTeX
@article{Kim2026,
  author = {Kim, Tae Min and Williamson, Stephen K and Papadopoulos, Kyriakos P and Hamid, Omid and Dy, Grace K and McDermott, Ray and Birnbaum, Ariel and Kaczmar, John M and Lakhani, Nehal and Rischin, Danny and Sarker, Debashis and Dowlati, Afshin and Zhu, Xin-Hua and Malhotra, Jyoti and Pouliot, Jean-Francois and Mani, Jayakumar and Brennan, Laura and Fang, Fang and Chen, Shuquan and Salvati, Mark and Lowy, Israel and Khaled, Ahmed and Lewis, Karl D and Kroog, Glenn and Fury, Matthew G and Cho, Byoung Chul},
  title = {Fianlimab, a human lymphocyte activation gene‐3 monoclonal antibody, in combination with cemiplimab: Tumor‐specific expansion cohorts in advanced malignancies},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {9},
  doi = {10.1002/cncr.70396}
}
Kostenlos starten →